Esperion to Acquire Corstasis Therapeutics for $75M Upfront, Expanding Cardiovascular Franchise with FDA-Approved Enbumyst
ESPR has more than doubled off its 52-week low of $0.693.
Summary
Esperion Therapeutics is acquiring Corstasis Therapeutics for $75 million upfront plus up to $180 million in milestones, adding the FDA-approved Enbumyst nasal spray to its cardiovascular franchise.
Key Events · M&A and Partnerships · ESPR
-
Acquisition Agreement
Esperion entered a definitive agreement to acquire Corstasis Therapeutics for $75 million in upfront cash.
-
Contingent Payments
Corstasis shareholders are eligible for up to an additional $180 million in regulatory and commercial milestones, plus low double-digit royalties on Enbumyst sales and follow-on products.
-
New Product Integration
The acquisition brings Enbumyst™ (bumetanide nasal spray), an FDA-approved diuretic for edema associated with congestive heart failure, hepatic, and renal disease, into Esperion's portfolio.
-
Strategic Expansion
This move is expected to leverage Esperion's existing cardiovascular commercial infrastructure, accelerate revenue growth, and address a multi-billion dollar U.S. market opportunity, aligning with its Vision 2040.
Analysis · ESPR · Life Sciences
Esperion Therapeutics is acquiring Corstasis Therapeutics, gaining global rights to Enbumyst, an FDA-approved nasal spray diuretic for edema associated with congestive heart failure, hepatic, and renal disease. This strategic acquisition, valued at $75 million upfront cash plus up to $180 million in potential regulatory and commercial milestones and low double-digit royalties, significantly expands Esperion's cardiovascular portfolio. The company plans to leverage its existing commercial infrastructure to drive double-digit revenue growth and address a multi-billion dollar market opportunity, aligning with its Vision 2040. The deal is expected to close in Q2 2026.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 40.7% of the 388 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.42%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ESPR was trading at $3.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $781.7M. The 52-week trading range was $0.69 to $4.18. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.